Table 2.
Quality assessment of included randomized controlled trials
| Trial | Blinded | Concealed allocation | Intention to treat analysis | Not stopped early for benefit | < 5 % Randomized Patients with Missing Outcome Data |
|---|---|---|---|---|---|
| CURE [3, 19] | Yes | Yes (central randomization) | Yes | Yes | Yes (0.1 %: 13/12,562 overall; 0 % of CABG) |
| PLATO [5, 17] | Yes | Yes (central randomization) | Yes | Yes | Yes (0.03 %: 5/18,624 overall) |
| TRITON-TIMI 38 [4, 11] | Yes | Yes (central randomization) | Yes | Yes | Yes (0.1 %: 14/13,608 overall) |
| CREDO [18, 20] | Yes | Yes | Yes | Yes | Yes (0 %) |
| CRYSSA [22] | No | Yes | Yes | Yes | Yes (0.3 %: 1/300) |
| CASCADE [21] | Yes | Yes | Yes | Yes | Yes (0 %) |
| Gao 2010 [15] | No | Unclear | Yes | Yes | Yes (3.7 %: 9/249) |
| Sun 2010 [16] | Yes | Yes | Yes | Yes | Yes (1.0 %: 1/100) |
| Gasparovic 2014 [23] | No | Yes | Yes | Yes | Yes (2.2 %: 5/224) |